Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Gilmore_O’Neill
|
| gptkbp:collaboratedWith |
gptkb:Allergan
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gene therapies
|
| gptkbp:focusesOn |
CRISPR technology
genome editing |
| gptkbp:foundedYear |
2013
|
| gptkbp:founder |
gptkb:Feng_Zhang
gptkb:Jennifer_Doudna gptkb:George_Church gptkb:David_Liu gptkb:J._Keith_Joung |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Editas Medicine
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:EDIT-101
gptkb:EDIT-301 |
| gptkbp:numberOfEmployees |
approximately 200 (as of 2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
EDIT
|
| gptkbp:target |
gptkb:Beta_thalassemia
gptkb:Leber_congenital_amaurosis gptkb:Sickle_cell_disease |
| gptkbp:website |
https://www.editasmedicine.com/
|
| gptkbp:bfsParent |
gptkb:David_R._Liu
gptkb:Feng_Zhang |
| gptkbp:bfsLayer |
4
|